MTOR and hematocrit: We hypothesize that cellular metabolism contributes to HT pathogenesis through T cell activation, that some metabolic sensors, such as mTOR and HIF-1α, influence autoimmune responses through metabolic pathways in HT, and that metabolic modulating treatments could be used to reduce or revert HT.